No registrations found.
ID
Source
Brief title
Sponsors and support
Dept. Gastroenterology & Hepatology
Dr. Molewaterplein 40
3015 GD Rotterdam
Intervention
Outcome measures
Primary outcome
Quality of life (questionnaires).
Secondary outcome
Patient satisfaction (questionnaire) costs.
Background summary
For patients with irresectabel of recurrent esophageal-, pancreatic- or
hepatobiliary cancer, no curative treatment options are available. The median survival for this group is only 2-10 months. The treatment aim in the palliative phase is to improve the quality of life of patients and
their family, through the prevention and relief of suffering by means of the identification and treatment of pain and other physical, psychosocial and spiritual problems. The high degree of physical and psychological problems in this phase suggest a need for close monitoring and support.
Presently, patients in the palliative phase of their disease visit the outpatient clinic for medical follow up. The frequency is usually low with a mean of every 8 weeks. These visits to the hospital are a burden for the majority of patients. We hypothesized that nurse-led follow up at home could be a valuable alternative for these patients. This study will evaluate nurse-led follow up for palliative GI cancer patients by home visits. Outcome will be compared with the usual medical follow up at the outpatient clinic. Outcome measures are: quality of life, patient satisfaction and costs.
Study objective
Does nurse-led follow up at home lead to improved quality of life an satifaction and a reduction of costs compared to medical follow up at the outpatient clinic, without compromising the medical condition of patients?
Intervention
Nurse led follow up at home at 2-weekly and later monthly intervals until month 13 or death versus medical follow up at the outpatient clinic at 1 month and thereafter every 2 months until month 13 or death.
Department of Gastroenterology and Hepatology
Room HS 512
P.O. Box 2040
P.D. Siersema
Rotterdam 3000 CA
The Netherlands
+31 (0)10 4632748 / +31 (0)10 4625946
p.siersema@erasmusmc.nl
Department of Gastroenterology and Hepatology
Room HS 512
P.O. Box 2040
P.D. Siersema
Rotterdam 3000 CA
The Netherlands
+31 (0)10 4632748 / +31 (0)10 4625946
p.siersema@erasmusmc.nl
Inclusion criteria
1. Patients with irresectabel of recurrent esophageal-, pancreatic- and hepatobiliary cancer, for whom no curative treatment options are available;
2. Informed consent.
Exclusion criteria
1. Not able to understand or read the Dutch language;
2. Undergoing treatment with chemotherapy or radiotherapy or a combination.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL628 |
NTR-old | NTR687 |
Other | : MEC-2005-176 |
ISRCTN | ISRCTN86515732 |